评估印度急性冠状动脉综合征 (ACS) 患者的LDL-C控制 - 一个回顾性的现实世界研究LDL-C控制在ACS中
Madhur Jain1, Rahul Sawant2, Hitanshu Panchal3
1Dr Madhu Jain's Clinic, New Delhi, India.
International journal of cardiology. Cardiovascular risk and prevention
|September 29, 2023
概括
在印度急性冠状动脉综合征 (ACS) 患者中,高强度他类药物治疗在大多数情况下无法达到目标低密度脂蛋白胆固醇 (LDL-C) 水平. 可能需要新的疗法来改善ACS后的LDL-C控制.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 药理学 药理学是指药理学的学科.
背景情况:
- 低密度脂蛋白胆固醇 (LDL-C) 是动脉样硬化心血管疾病 (ASCVD) 的关键危险因素.
- 尽管使用了降脂疗法,但在ASCVD患者中,残留性脂质失调是常见的.
- 有效的LDL-C控制对于急性冠状动脉综合征 (ACS) 后的二次预防至关重要.
研究的目的:
- 评估印度ACS患者脂质管理的现实世界治疗模式.
- 评估ACS事件发生一年后达到目标LDL-C水平的程度.
- 了解当前降脂策略在这个人群中的有效性和耐受性.
主要方法:
- 一个真实世界,描述性,回顾性,观察性,多中心研究在印度.
- 在ACS事件发生后的一年内收集的数据.
- 评估了LDL-C,脂质概况和治疗模式的变化,并注意到不良事件.
主要成果:
- 分析了575名印度ACS患者 (平均年龄52.9岁,76.35%男性).
- 平均的LDL-C从122.64 mg/dL显著降低到74.41 mg/dL (p < 0.001).
- 只有20.87%的LDL-C达到<55 mg/dL,而55.65%的LDL-C没有达到<70 mg/dL,尽管使用高强度的他类药物.
结论:
- 大多数接受高强度他类药物的印度ACS患者无法达到目标的LDL-C水平.
- 目前的降脂策略可能不足以在ACS后实现最佳的LDL-C控制.
- 建议考虑新疗法,以提高疗效和指导方针的遵守.
相关概念视频
Coronary Artery Disease IV: Preventive Measures
23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Acute Coronary Syndrome III: Diagnostic Studies
9
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
9
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11


